Analyst Forecasts $5bn Sales For Moderna Vaccine – But Much Still Hangs In The Balance

Bullish Outlook From Jefferies

COVID-19 success could catapult Moderna into the same biotech breakthrough realm as Regeneron and Vertex, but the accelerated venture remains risky.

Moderna_Pills_Syringe
Moderna has a cytomegalovirus (CMV) vaccine in its pipeline, which could be boosted by a COVID-19 success

Following publication of full Phase I data from its COVID-19 vaccine (jointly developed with the US National Institutes of Health), Moderna, Inc.’s share price has once again shot up, and now stands at $82 a share. 

This is a four-fold increase on its pre-pandemic share price in January this year, bringing its market capitalisation to just short of $32bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

 

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.